{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:02:43Z","timestamp":1772902963846,"version":"3.50.1"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Padiatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Survival in high-risk neuroblastoma has improved with multimodal treatment\n                        approaches and numerous studies have focused on treatment-related side\n                        effects. This study examines the prevalence, severity and risks of late\n                        effects following high-dose chemotherapy and autologous stem cell\n                        transplantation in high risk neuroblastoma patients.<\/jats:p>\n                  <jats:p>This study included high-risk neuroblastoma patients who underwent autologous\n                        stem cell transplantation and survived 5 years without relapse in a single\n                        center.<\/jats:p>\n                  <jats:p>Of the 41 patients who received high-dose chemotherapy and autologous stem\n                        cell transplantation, 20 patients survived without relapse for at least 5\n                        years and were included in the analysis. Amid 20 patients, 12 patients (60%)\n                        were men. The median age of the patients was 13.5 years at the last follow\n                        up. After six cycles of induction chemotherapy, 11 patients (55%) received\n                        busulfan\u2013melphalan as the consolidation regimen, while 9 patients (45%)\n                        received carboplatin\u2013etoposide\u2013melphalan. The median follow-up after\n                        transplantation was 9 years. At least one complication occurred in 19 out of\n                        20 patients (95%). Severe late complications were observed in seven\n                        patients. Two patients developed treatment-related secondary neoplasms. In\n                        contrast to the literature, the most common adverse event was focal nodular\n                        hyperplasia (40%) in the liver. The second most common adverse event was\n                        ovarian failure (37.5%) and the third most common was hearing loss (35%).\n                        Endocrine pathologies were more common in patients receiving\n                        busulfan\u2013melphalan as the consolidation regimen.<\/jats:p>\n                  <jats:p>This study highlights the future risks of side effects in high-risk\n                        neuroblastoma survivors and emphasizes the need for a long-term\n                        follow-up.<\/jats:p>","DOI":"10.1055\/a-2815-2484","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:03:11Z","timestamp":1771459391000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Long-Term Late Side Effects in High-Risk Neuroblastoma\n                    Patients Undergoing Autologous Bone Marrow Transplantation"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2675-1150","authenticated-orcid":false,"given":"R\u0131za","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ege University, Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulcihan","family":"Ozek","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Ege University, Izmir,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eda","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Ege University, Izmir,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serap","family":"Aksoylar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Ege University, Izmir,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1053\/j.semnuclmed.2011.05.001","article-title":"Pediatrics: Diagnosis of neuroblastoma","volume":"41","author":"S E Sharp","year":"2011","journal-title":"Semin Nucl Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12098-017-2298-0","article-title":"Management of neuroblastoma: ICMR consensus document","volume":"84","author":"D Bansal","year":"2017","journal-title":"Indian J Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"B Qiu","year":"2022","journal-title":"Nat Rev Clin Oncol Nat Res"},{"issue":"07","key":"ref4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/pbc.24452","article-title":"Long-term follow-up of children with high-risk neuroblastoma: The ENSG5 trial\n                    experience","volume":"60","author":"L Moreno","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1055-9965.EPI-16-0812","article-title":"Approach for classification and severity grading of long-term and late-onset\n                    health events among childhood cancer survivors in the St. Jude lifetime\n                    cohort","volume":"26","author":"M M Hudson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"ref8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2352-4642(25)00241-X","article-title":"Late effects after high-risk neuroblastoma (LEAHRN): a multicentre,\n                    cross-sectional cohort study from the Children\u2019s Oncology Group","volume":"9","author":"T O Henderson","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"08","key":"ref9","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1038\/s41409-021-01258-1","article-title":"Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose\n                    chemotherapy and stem cell transplantation rescue","volume":"56","author":"S Haghiri","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/pbc.23036","article-title":"Survival and late effects in children with stage 4 neuroblastoma","volume":"57","author":"T Perwein","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"03","key":"ref11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/pbc.20331","article-title":"Long-term complications in survivors of advanced stage neuroblastoma","volume":"45","author":"C Laverdi\u00e8re","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejca.2017.06.035","article-title":"Second malignant neoplasms after childhood non-central nervous system embryonal\n                    tumours in North America: A\u2009population-based study","volume":"84","author":"X Zong","year":"2017","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/ijc.11455","article-title":"Long-term risk of second malignant neoplasms after neuroblastoma in childhood:\n                    Role of treatment","volume":"107","author":"C Rubino","year":"2003","journal-title":"Int J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.ctrv.2022.102355","article-title":"Neuroblastoma survivors at risk for developing subsequent neoplasms: A\n                    systematic review","volume":"104","author":"AS R Westerveld","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"04","key":"ref15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1667\/RR3605.1","article-title":"Thyroid cancer in childhood cancer survivors: A detailed evaluation of radiation\n                    dose response and its modifiers","volume":"166","author":"C M Ronckers","year":"2006","journal-title":"Radiat Res"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1089\/thy.2011.0464","article-title":"Differentiated thyroid carcinoma after I-MIBG treatment for neuroblastoma during\n                    childhood: Description of the first two cases","volume":"22","author":"H M van Santen","year":"2012","journal-title":"Thyroid"},{"issue":"02","key":"ref17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/pbc.26212","article-title":"Long-term auditory complications after childhood cancer: A report from the swiss\n                    childhood cancer survivor study","volume":"64","author":"A Weiss","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"07","key":"ref18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/sj.bmt.1701391","article-title":"Severe ototoxicity following carboplatin-containing conditioning regimen for\n                    autologous marrow transplantation for neuroblastoma","volume":"22","author":"S Parsons","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"06","key":"ref19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2013.51.2038","article-title":"Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors,\n                    and concordance of grading scales\u2014a report from the Children\u2019s Oncology\n                    Group","volume":"32","author":"W Landier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose\n                    chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international,\n                    randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"R Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"ref21","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1016\/j.ejca.2009.06.032","article-title":"Persistent nephrotoxicity during 10-year follow-up after cisplatin or\n                    carboplatin treatment in childhood: Relevance of age and dose as risk\n                    factors","volume":"45","author":"R Skinner","year":"2009","journal-title":"Eur J Cancer"},{"issue":"02","key":"ref22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/bmt.2008.304","article-title":"Focal nodular hyperplasia of the liver following hematopoietic SCT","volume":"43","author":"H Sudour","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"06","key":"ref23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00431-010-1388-z","article-title":"Focal nodular hyperplasia of the liver after intensive treatment for pediatric\n                    cancer: Is hematopoietic stem cell transplantation a risk factor?","volume":"170","author":"R Masetti","year":"2011","journal-title":"Eur J Pediatr"},{"issue":"03","key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29537","article-title":"Late effects in survivors of high-risk neuroblastoma following stem cell\n                    transplant with and without total body irradiation","volume":"69","author":"W L Hobbie","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"05","key":"ref25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/pbc.21683","article-title":"Late effects in survivors of tandem peripheral blood stem cell transplant for\n                    high-risk neuroblastoma","volume":"51","author":"W L Hobbie","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.critrevonc.2020.102924","article-title":"Role and toxicity of radiation therapy in neuroblastoma patients: A literature\n                    review","volume":"149","author":"Q Zhao","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"04","key":"ref27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/pbc.22593","article-title":"Hypothyroidism after treatment of metastatic neuroblastoma","volume":"55","author":"H Lackner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"ref28","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/pbc.25162","article-title":"Ovarian insufficiency and pubertal development after hematopoietic stem cell\n                    transplantation in childhood","volume":"61","author":"D Bresters","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"ref29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bmt.1701483","article-title":"Ovarian function after autologous bone marrow transplantation in childhood:\n                    High-dose busulfan is a major cause of ovarian failure","volume":"22","author":"C Teinturier","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"05","key":"ref30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.1988.6.5.813","article-title":"Ovarian function following marrow transplantation for aplastic anemia or\n                    leukemia","volume":"6","author":"J E Sanders","year":"1988","journal-title":"J Clin Oncol"}],"container-title":["Klinische P\u00e4diatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2815-2484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:48:04Z","timestamp":1772840884000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2815-2484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1055\/a-2815-2484","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0300-8630","1439-3824"],"issn-type":[{"value":"0300-8630","type":"print"},{"value":"1439-3824","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,18]]},"published":{"date-parts":[[2026,2,18]]}}}